Ion Anghelescu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ion Anghelescu has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Arnim Quante
Charité - University Medicine Berlin, Campus Benjamin Franklin, Department of Psychiatry and Psychotherapy, Berlin, Germany
5 shared publications - Francesca Regen
Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Neurobiology Laboratory, Dept. of Psychiatry, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany
4 shared publications - Isabella Heuser
Charité - Universitaetsmedizin Berlin, Department of Psychiatry and Neurosciences, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany
4 shared publications - Sara Zeugmann
Department of Psychiatry and Psychotherapy, Charité, University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany,
3 shared publications - Alexander Luborzewski
Department of Psychiatry, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Eschenallee 3, D-14050 Berlin, Germany
2 shared publications - Armin Szegedi
Department of Psychiatry, University of Mainz, Mainz, Germany
2 shared publications
Latest Publications
- 29 April 2021
- Published by Springer Nature
- p. 1-8
Psychostimulants
- 1 January 2021
- Published by Springer Nature
- p. 134-140
Antidepressant Drugs
- 26 April 2018
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 378 (17) , 1648-1650
Prazosin for Post-Traumatic Stress Disorder
- 26 April 2018
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 378 (17) , 1648-1650
Prazosin for Post-Traumatic Stress Disorder
- 1 January 2016
- Published by Elsevier in The Lancet
- Vol. 387 (10015) , 224-225
Methadone for prisoners
- 1 September 2013
- Vol. 25 (3) , 214-20
Quetiapine as combination treatment with citalopram in unipolar depression with prominent somatic symptoms: a randomised, double-blind, placebo-controlled pilot study.
Patients with major depressive disorder (MDD) accompanied by physical symptoms may be less responsive to antidepressant treatment. Quetiapine has been evaluated in the treatment of bipolar depression and has been recently approved as an add-on therapy for unipolar depression. Less is known about the efficacy of combination therapies in patients suffering from MDD with somatic symptoms. The aim of the present study was to evaluate the efficacy of quetiapine as adjunctive therapy to the SSRI citalopram in patients with MDD and somatic complaints. 41 inpatients with nonpsychotic DSM-IV MDD experiencing significant symptoms of somatic distress as defined by a baseline score on the SCL-90-R somatization subscale greater one standard deviation above adult nonpatient norms were randomly assigned to receive either citalopram 40 mg/day plus placebo (n=20) or citalopram 40 mg/day plus quetiapine, 300 to 600 mg/day (n=21) for 6 weeks. The primary outcome measure was the Hamilton Depression Rating Scale (HDRS) score. Mean changes in HDRS scores from baseline to week 6 using last-observation-carried-forward methods were -12.3±6.2 and -10.7±5.1 in the citalopram-quetiapine and citalopram-placebo group, respectively. Remission rates were significant higher in the citalopram-quetiapine-group (41.1%) than in the citalopram-placebo-group (26.3%), respectively. Although quetiapine as add-on to citalopram did not separate statistically from placebo on the HDRS score in improving depressive symptoms and somatic symptoms in patients with MDD and prominent somatic complaints, higher remission rates and other second outcome parameters showed advantages for quetiapine. Larger, double-blind, placebo-controlled trials of quetiapine as augmentation therapy in MDD with somatic symptoms are warranted.
- 1 September 2013
- Vol. 25 (3) , 214-20
Quetiapine as combination treatment with citalopram in unipolar depression with prominent somatic symptoms: a randomised, double-blind, placebo-controlled pilot study.
Patients with major depressive disorder (MDD) accompanied by physical symptoms may be less responsive to antidepressant treatment. Quetiapine has been evaluated in the treatment of bipolar depression and has been recently approved as an add-on therapy for unipolar depression. Less is known about the efficacy of combination therapies in patients suffering from MDD with somatic symptoms. The aim of the present study was to evaluate the efficacy of quetiapine as adjunctive therapy to the SSRI citalopram in patients with MDD and somatic complaints. 41 inpatients with nonpsychotic DSM-IV MDD experiencing significant symptoms of somatic distress as defined by a baseline score on the SCL-90-R somatization subscale greater one standard deviation above adult nonpatient norms were randomly assigned to receive either citalopram 40 mg/day plus placebo (n=20) or citalopram 40 mg/day plus quetiapine, 300 to 600 mg/day (n=21) for 6 weeks. The primary outcome measure was the Hamilton Depression Rating Scale (HDRS) score. Mean changes in HDRS scores from baseline to week 6 using last-observation-carried-forward methods were -12.3±6.2 and -10.7±5.1 in the citalopram-quetiapine and citalopram-placebo group, respectively. Remission rates were significant higher in the citalopram-quetiapine-group (41.1%) than in the citalopram-placebo-group (26.3%), respectively. Although quetiapine as add-on to citalopram did not separate statistically from placebo on the HDRS score in improving depressive symptoms and somatic symptoms in patients with MDD and prominent somatic complaints, higher remission rates and other second outcome parameters showed advantages for quetiapine. Larger, double-blind, placebo-controlled trials of quetiapine as augmentation therapy in MDD with somatic symptoms are warranted.
- 1 September 2013
- Vol. 25 (3) , 227-35
Childhood maltreatment and adult proinflammatory status in patients with major depression.
An increasing body of research considers the immunological effects of major depression. It remains an open question, whether depression itself acts in an immunomodulatory fashion or whether other factors related to depression result in these immunological effects. Regardless, major depression is often the result of early life stress, the implications of which are not satisfactorily understood. Early life stress was retrospectively evaluated in 25 depressed inpatients via the CTQ (Childhood Trauma Questionnaire). Its impact on immunological biomarkers (fibrinogen, SAA, CRP, adiponectin, TNF-α, resistin, and sE-selectin) in adulthood was assessed via multiple regression analyses. Parental bonding was assessed via the PBI (Parental bonding questionnaire), severity of depression with the HDRS-17 (Hamilton-Depression-Rating Scale). Nearly all patients had experienced a parental style of affectionless control. Physical neglect significantly predicted fibrinogen levels (R(2)=0.42, adjusted R(2)=0.27, β=0.56, p=0.04). Severity of depression was not associated with immune markers. Childhood maltreatment was linked to fibrinogen levels in our sample. Thus, inflammation may be an important mechanism mediating the adverse effects of early life stress on adult health in patients with major depression.
- 1 September 2013
- Vol. 25 (3) , 227-35
Childhood maltreatment and adult proinflammatory status in patients with major depression.
An increasing body of research considers the immunological effects of major depression. It remains an open question, whether depression itself acts in an immunomodulatory fashion or whether other factors related to depression result in these immunological effects. Regardless, major depression is often the result of early life stress, the implications of which are not satisfactorily understood. Early life stress was retrospectively evaluated in 25 depressed inpatients via the CTQ (Childhood Trauma Questionnaire). Its impact on immunological biomarkers (fibrinogen, SAA, CRP, adiponectin, TNF-α, resistin, and sE-selectin) in adulthood was assessed via multiple regression analyses. Parental bonding was assessed via the PBI (Parental bonding questionnaire), severity of depression with the HDRS-17 (Hamilton-Depression-Rating Scale). Nearly all patients had experienced a parental style of affectionless control. Physical neglect significantly predicted fibrinogen levels (R(2)=0.42, adjusted R(2)=0.27, β=0.56, p=0.04). Severity of depression was not associated with immune markers. Childhood maltreatment was linked to fibrinogen levels in our sample. Thus, inflammation may be an important mechanism mediating the adverse effects of early life stress on adult health in patients with major depression.
- 1 September 2013
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 23 (9) , 1043-1050
Does early improvement predict response to the fast-dissociating D2 receptor antagonist JNJ-37822681 in patients with acute schizophrenia? ☆
- 1 September 2013
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 23 (9) , 1043-1050
Does early improvement predict response to the fast-dissociating D2 receptor antagonist JNJ-37822681 in patients with acute schizophrenia? ☆
- 1 March 2012
- Vol. 24 (1) , 57-65
Pathways linking early life stress, metabolic syndrome, and the inflammatory marker fibrinogen in depressed inpatients.
Previous research has shown that metabolic syndrome as well as early life stress can account for immunoactivation (e.g. in the form of altered fibrinogen levels) in patients with major depression. This study aims at assessing the relationship between components of metabolic syndrome, early life stress and fibrinogen levels, taking the severity of depression into consideration. Measures of early life stress and signs of metabolic syndrome were collected in 58 adult inpatients diagnosed with depression. The relationships between the factors were assessed by means of path analyses. Two main models were tested: the first model with metabolic syndrome mediating between early life stress and fibrinogen levels and the second model without the mediating effect of metabolic syndrome. The first model was not supported by our data (χ²=7.02, df=1, p=0.008, CFI=0.00, NNFI=-9.44, RMSEA=0.50). The second model however provided an excellent fit for the data (χ²=0.02, df=1, p=0.90, CFI=1.00, NNFI=2.71, RMSEA=0.00). Extending the models by introducing severity of depression into them did not yield good indices of fit. The developmental trajectory between early life stress and inflammation appears not to be mediated by metabolic syndrome associated factors in our sample. Possible reasons including severity and type of early life stress, as well as potential epigenetic influences are discussed.
- 1 March 2012
- Vol. 24 (1) , 57-65
Pathways linking early life stress, metabolic syndrome, and the inflammatory marker fibrinogen in depressed inpatients.
Previous research has shown that metabolic syndrome as well as early life stress can account for immunoactivation (e.g. in the form of altered fibrinogen levels) in patients with major depression. This study aims at assessing the relationship between components of metabolic syndrome, early life stress and fibrinogen levels, taking the severity of depression into consideration. Measures of early life stress and signs of metabolic syndrome were collected in 58 adult inpatients diagnosed with depression. The relationships between the factors were assessed by means of path analyses. Two main models were tested: the first model with metabolic syndrome mediating between early life stress and fibrinogen levels and the second model without the mediating effect of metabolic syndrome. The first model was not supported by our data (χ²=7.02, df=1, p=0.008, CFI=0.00, NNFI=-9.44, RMSEA=0.50). The second model however provided an excellent fit for the data (χ²=0.02, df=1, p=0.90, CFI=1.00, NNFI=2.71, RMSEA=0.00). Extending the models by introducing severity of depression into them did not yield good indices of fit. The developmental trajectory between early life stress and inflammation appears not to be mediated by metabolic syndrome associated factors in our sample. Possible reasons including severity and type of early life stress, as well as potential epigenetic influences are discussed.